George Somlo focuses on Internal medicine, Oncology, Breast cancer, Surgery and MEDLINE. His work in Multiple myeloma, Chemotherapy, Combination therapy and Bone marrow are all subfields of Internal medicine research. His Oncology study combines topics from a wide range of disciplines, such as Clinical trial, Disease, Trastuzumab and General surgery.
His Breast cancer study combines topics in areas such as Radiation therapy and Adjuvant therapy. The various areas that he examines in his Surgery study include Gastroenterology and Thalidomide. The Cancer study combines topics in areas such as Cancer research and Adverse effect.
His primary areas of investigation include Internal medicine, Oncology, Breast cancer, Chemotherapy and Surgery. His Internal medicine study typically links adjacent topics like Gastroenterology. The concepts of his Oncology study are interwoven with issues in Carboplatin, Trastuzumab, Adjuvant therapy and Pathology.
His Breast cancer research is multidisciplinary, relying on both Cancer research, Clinical trial and Radiation therapy. George Somlo has included themes like Regimen, Toxicity and Pharmacology in his Chemotherapy study. Many of his studies involve connections with topics such as Thalidomide and Surgery.
George Somlo mostly deals with Internal medicine, Oncology, Breast cancer, Cancer research and Cancer. Internal medicine is closely attributed to Gastroenterology in his work. George Somlo has researched Oncology in several fields, including Chemotherapy, Lenalidomide, Carboplatin, Adjuvant chemotherapy and Metastatic breast cancer.
His Breast cancer research incorporates elements of Biopsy and Immune system. His studies deal with areas such as Carcinogenesis, Palbociclib, STAT3, Triple-negative breast cancer and Estrogen as well as Cancer research. His Cancer study incorporates themes from Neurosurgery, Mesenchymal stem cell and Neurooncology.
His primary scientific interests are in Internal medicine, Oncology, Breast cancer, Cancer research and Cancer. His work often combines Internal medicine and PARP inhibitor studies. He combines subjects such as Nausea, Carboplatin, Chemotherapy and Pharmacology with his study of Oncology.
His work carried out in the field of Breast cancer brings together such families of science as Disease management, Disease and Retrospective cohort study. His studies in Cancer research integrate themes in fields like Carcinogenesis, PI3K/AKT/mTOR pathway, Estrogen receptor, STAT3 and Triple-negative breast cancer. His research in the fields of Cancer stem cell, Metastasis and Metastatic breast cancer overlaps with other disciplines such as Leptin.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Maximilian Diehn;Robert W. Cho;Neethan A. Lobo;Tomer Kalisky.
Clinical practice guidelines in oncology
William J. Gradishar;Benjamin O. Anderson;Ron Balassanian;Sarah L. Blair.
Journal of The National Comprehensive Cancer Network (2018)
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
Thomas J. Smith;James Khatcheressian;Gary H. Lyman;Howard Ozer.
Journal of Clinical Oncology (2006)
Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells
Yohei Shimono;Maider Zabala;Robert W. Cho;Neethan Lobo.
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
William M. Sikov;Donald A. Berry;Charles M. Perou;Baljit Singh.
Journal of Clinical Oncology (2015)
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel;Thomas Martin;Michael Wang;Ravi Vij.
Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis
Miranda Y. Fong;Weiying Zhou;Liang Liu;Aileen Y. Alontaga.
Nature Cell Biology (2015)
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
Thomas J. Smith;Kari Bohlke;Gary H. Lyman;Kenneth R. Carson.
Journal of Clinical Oncology (2015)
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
David G. Maloney;Arthur J. Molina;Firoozeh Sahebi;Keith E. Stockerl-Goldstein.
Breast cancer: Clinical practice guidelines in oncology
Robert W. Carlson;Benjamin O. Anderson;Harold J. Burstein;Charles E. Cox.
Journal of The National Comprehensive Cancer Network (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: